Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Demonstrated
TAGRISSO® (osimertinib) demonstrated strong overall survival benefit in the ADAURA Phase III trial…
First Phase III trial to demonstrate survival benefit in this adjuvant setting
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a…
OCTO Telematics Applauded by Frost & Sullivan for Its Versatile Telematic Solutions and…
OCTO's exceptional customer acquisition and retention strategies, customer-centric framework, and unmatched customer value position it to drive the telematics UBI space into its next growth phase.
SAN ANTONIO, Dec. 14, 2022 /PRNewswire/…
AR-Enabled Manifest Work-Instruction Platform to Be Demonstrated at Department of Defense…
SEATTLE--(BUSINESS WIRE)--Taqtile, Inc. will exhibit its industry-leading augmented reality (AR)-based work-instruction platform, Manifest®, at the 2022 Department of Defense (DoD) Maintenance Symposium in Orlando, December 12-15.…
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in…
Trial met its primary endpoint with Onivyde® (irinotecan liposome injection) in the NALIRIFOX treatment regimen showing statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine regimen…